SOLUTION OF THE PROBLEM OF PSEUDOMONAS INFECTION IN CHILDREN WITH CYSTIC FIBROSIS
https://doi.org/10.15690/vsp.v13i1.913
Abstract
A difficult problem of Pseudomonas infection antibacterial treatment in patients with cystic fibrosis and its historical aspects are discussed in this article. Different medicinal forms of antibiotics are compared; the dosages for treatment in cystic fibrosis are shown. Efficacy and safety of inhalation form of tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas infection are considered. Appropriateness of its administration in order to eradicate Pseudomonas aeruginosa as soon as it is found in the sputum, as well as in chronic persistence of this pathogen to prevent relapses of bronchopulmonary process and improvement of pulmonary function and microbiological stability is shown. The authors demonstrate their own data on usage of this drug, confirming its high tolerability and clinical effect.
About the Authors
O. I. Simonova
Scientific Centre of Children Health, Moscow
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
PhD, professor, Head of the Department of Pneumology and Allergology, RAMS
Russian Federation
PhD, professor, Head of the Department of Pneumology and Allergology, RAMS
Yu. V. Gorinova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
A. V. Lazareva
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
L. K. Katosova
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
N. I. Burkina
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
V. P. Chernevich
Scientific Centre of Children Health, Moscow
Russian Federation
Russian Federation
References
1. Dodge J.A., Lewis P.A., Stanton M. et al. Cystic fibrosis mortality and survival in the United Kingdom, 1947 to 2003. Eur. Respir. J. 2006; 20: 4–51.
2. Krasovskii S.A., Chernyak A.V., Amelina E.L., Nikonova V.S., Voronkova A.Yu., Samoilenko V.A., Naumenko Zh.K., Kashirskaya N.Yu., Kapranov N.I., Sherman V.D., Shabalova L.A., Chistyakova V.P., Simonova O.I., Semykin S.Yu., Gorinova Yu.V., Avakyan L.V., Petrova P.N., Kusova Z.A., Usacheva M.V., Samsonova M.V. Dynamics of survival in patients with cystic fibrosis in Moscow and the Moscow region in 1992-2001 and 2002-2011. Pul'monologiya = Pulmonology. 2012; 3: 79–87.
3. Cystic Fibrosis Mutation Database. Available at: www.genet.sickkids.on.ca/cftr
4. Simonova O.I. Applications of dornase alfa in pediatric practice. Vopr. sovr. pediatrii = Current pediatrics. 2011; 10 (4): 145–152.
5. Armstrong D.S., Grimwood K., Carlin J.B. et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997; 156: 1197–1204.
6. Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus J. Cyst. Fibrosis. 2005; 4: 7–26.
7. Hoiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr. Scand. Suppl. 1982; 301: 33–54.
8. Botzenhart K., Doring G. Epidemiology and ecology of Pseudomonas aeruginosa. In: Pseudomonas aeruginosa as an opportunistic pathogen. M. Campa, M. Bendineli, H. Friedman (eds.). New York: Plenum Press. 1993. P. 1–18.
9. Doring G., Knight R., Bellon G. Immunology of cystic fibrosis. In: Cystic Fibrosis. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. M.E. Morlin, G.L. Hedges, A.L. Smith, J.L. Burns (eds.). J. Clin. Microbiol. 1994; 32: 1027–1030.
10. Sheppard M.N. The pathology of cystic fibrosis. In: Cystic Fibrosis. M.E. Hodson, D. Geddes (eds.). London: Chapman and Hall. 1995. P. 131–149.
11. Rosenfeld M., Ramsey B.W., Gibson R.L. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 2003; 9 (6): 492–497.
12. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997; 23 (5): 330–335.
13. Sharma G.D., Tosi M.F., Stern R.C., Davis P.B. Progression of pulmonary disease after disappearance of Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 169–173.
14. Corey M., Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am. J. Epidemiol. 1996; 143: 1007–1017.
15. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 1990; 116: 714–719.
16. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002; 34 (2): 277–287.
17. Matsui H., Grubb B.R., Tarran R. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of CF airways disease. Cell. 1998; 95: 1005–1015.
18. Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of CF patients. Clin. Invest. 2002; 109: 317–325.
19. Ramsey B.W., Pepe M.S., Quan J.M. et al Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–30.
20. Michel B.C. Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987. Chest. 1988; 94: 129–140.
21. Blumer J.L., Stern R.C., Klinger J.D. et al. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant Pseudomonas. Am. J. Med. 1985; 79: 37–46.
22. Doring G., Conway S.P. et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur. Respir. J. 2000; 16: 749–767.
23. Smith M.J., White L.O., Bowyer H., Willis J., Hodson M.E. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob. Agents Chemother. 1986; 30: 614–616.
24. Hodson M.E., Roberts C.M., Butland R.J., Smith M.J. Oral ciprofloxacin compared with conventional intravenous treatment for P. aeruginosa infection in adults with cystic fibrosis. Lancet. 1987; 1: 235–237.
25. Shalit I., Stutman H.R., Marks M.I., Chartrand S.A., Hilman B.C Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am. J. Med. 1987; 82: 189–195.
26. Noah T.L., Ivins S.S., Abode K.A., Stewart P.W., Michelson P.H., Harris W.T., Henry M.M., Leigh M.W. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr. Pulmonol. 2010; 45 (3): 281–290.
27. Lillquist Y.P., Cho E., Davidson A.G. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J. Cyst. Fibrosis. 2011; 10 (3): 175–180.
28. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibrosis. 2013; 12 (1): 29–34.
29. Taccetti G., Bianchini E., Cariani L. et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax. 2012; 67 (10): 853–859.
30. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286–291.
31. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N. et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 2011; 165 (9): 847–856.
32. Kondrat'eva I.I., Kapranov N.I., Kashirskaya N.Yu., Sherman V.D. Cystic fibrosis in children and adults, a look into the future. Pediatriya im. G.N. Speranskogo – PEDIATRIYA. 2014; 92 (4): 142–144.
33. Simonova O.I., Lazareva A.V., Motuzova O.V., Ponomarenko O.A., Katosova L.K., Chistyakova V.P., Burkina N.I. New features of antibiotic therapy in acute and chronic respiratory diseases in children. Vopr. sovr. pediatrii = Current pediatrics. 2013; 12 (1): 123–130.
34. Lazareva A.V. Sovremennyi spektr vozbuditelei khronicheskogo vospaleniya pri boleznyakh organov dykhaniya u detei i optimizatsiya antibakterial'noi terapii. Avtoref. dis. … kand. med. nauk [Modern Range of Pathogens of Chronic Inflammation in Respiratory Diseases in Children and Optimization of Antibiotic Therapy. Author’s abstract]. Moscow, 2010. 24 p.
35. Poli G. et al. Clinical pharmacology study of Bramitob, a Tobramicyn Solution for Nebulization, in Comparison with Tobi. Pediatr. Drugs. 2007; 9 (Suppl. 1): 3–9.
36. Chuchalin A., Kapranov N. et al. A formulation of aerosolized tobramycin (BramitobR) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Drugs. 2007; 9 (Suppl. 1): 21–31.
37. Amelina E.L., Chuchalin A.G. Inhaled tobramycin in the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pul'monologiya = Pulmonology. 2009; 5: 120–126.
38. Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs. 2007; 9: 11–20.
39. Simonova O.I. nhalation therapy: what determines its effectiveness? Vopr. sovr. pediatrii = Current pediatrics. 2008; 7 (4): 126–131.
40. Khrushchev S.V., Simonova O.I. Fizicheskaya kul'tura detei s zabolevaniyami organov dykhaniya: uch. pos. dlya studentov vuzov [Physical Education of Children with Respiratory Diseases: Manual for Students]. Mоscow, Akademiya, 2006. 304 p.
Review
For citations:
Simonova O.I., Gorinova Yu.V., Lazareva A.V., Katosova L.K., Burkina N.I., Chernevich V.P. SOLUTION OF THE PROBLEM OF PSEUDOMONAS INFECTION IN CHILDREN WITH CYSTIC FIBROSIS. Current Pediatrics. 2014;13(1):66-73. (In Russ.) https://doi.org/10.15690/vsp.v13i1.913
Views:
1150
Email this article 
